Business Context and Reporting Period
This Form 8-K, dated June 5, 2025, reports on the special meeting of stockholders held by GlycoMimetics, Inc. (the "Company") to approve a merger with Crescent Biopharma, Inc. ("Crescent"). Upon completion, GlycoMimetics will be renamed "Crescent Biopharma, Inc." and will operate as the parent of the combined entity. The filing details the voting results for ten proposals related to the merger, corporate restructuring, and governance.
Key Financial and Corporate Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period. Key corporate metrics disclosed include:
- Shares Outstanding (Pre-Split): 64,532,091 shares as of the May 13, 2025 record date.
- Shares Represented at Meeting: 48,584,725 shares (constituting a quorum).
- Reverse Stock Split Ratio: 1-for-100.
- Expected Post-Split Shares (GlycoMimetics): Approximately 0.6 million shares.
- Expected Post-Merger Total Shares: Approximately 14.8 million issued and outstanding; approximately 25.3 million on a fully-diluted basis.
- Authorized Shares: Increased from 150,000,000 to 175,000,000.
- New Ticker Symbol: CBIO (effective June 16, 2025).
Material Changes and Voting Results
Stockholders approved all ten proposals submitted at the special meeting. Material changes include:
- Merger Approval: Stockholders approved the issuance of shares representing more than 20% of the pre-merger outstanding stock to Crescent shareholders and the resulting change of control.
- Reverse Stock Split: The board approved a 1-for-100 reverse stock split to reduce the share count from ~64.5 million to ~0.6 million prior to the merger closing.
- Redomestication: Approval was granted to redomesticate the company from Delaware to the Cayman Islands.
- Compensation Plans: Stockholders approved the Crescent Biopharma 2025 Stock Incentive Plan and Employee Stock Purchase Plan.
- Executive Compensation: Advisory votes approved compensation arrangements for named executive officers related to the merger and general executive compensation.
Outlook, Risks, and Management Commentary
Outlook and Next Steps:
- The combined company is expected to commence trading on Nasdaq under the ticker "CBIO" on June 16, 2025.
- The merger closing is subject to the satisfaction or waiver of conditions set forth in the Merger Agreement.
- PricewaterhouseCoopers LLP is expected to be appointed as the independent registered public accounting firm for the combined company.
- Closing Conditions: Risks include the failure to satisfy closing conditions or the inability to complete the proposed pre-closing financing.
- Regulatory and Listing: Uncertainty regarding continued Nasdaq listing for GlycoMimetics until closing and the combined company's ability to remain listed post-merger.
- Financial Impact: Potential delays could impact anticipated cash resources, and unanticipated costs could reduce the combined company's liquidity.
- Legal Proceedings: Risks related to potential legal actions against the companies or their directors regarding the merger.
Investor Verification Checklist
- Verify the final closing date of the merger and the satisfaction of all conditions precedent.
- Confirm the effective date of the 1-for-100 reverse stock split and the treatment of fractional shares.
- Monitor the commencement of trading under the new ticker symbol "CBIO" on June 16, 2025.
- Review the definitive proxy statement (Form S-4) for detailed terms of the merger agreement and exchange ratios.
- Check for any updates regarding the pre-closing financing required to support the combined entity.